DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition (HQ PDF)

Cover
9781975184681_WEB V1
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 1
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART I Etiology and Prevention of Cancer
Global Cancer Incidence and Mortality
INTRODUCTION
DATA SOURCES
MEASURES OF BURDEN
MEASURES OF RISK
DEMOGRAPHIC FACTORS THAT AFFECT CANCER RISK
GLOBAL PATTERNS OF CANCER RISK AND BURDEN
PATTERNS OF MOST COMMON CANCERS
ISSUES IN INTERPRETING TEMPORAL TRENDS
FUTURE BURDEN OF CANCER
CONCLUSION
Tobacco Use and the Cancer Patient
INTRODUCTION
TOBACCO USE EPIDEMIOLOGY, ADDICTION, AND TOBACCO PRODUCT EVOLUTION
ELECTRONIC NICOTINE DELIVERY SYSTEMS, OR ELECTRONIC CIGARETTES
DEFINING TOBACCO USE BY THE CANCER PATIENT
EPIDEMIOLOGY OF TOBACCO USE AND CESSATION BY CANCER PATIENTS
SMOKING CESSATION IN THE CONTEXT OF LUNG CANCER SCREENING
THE CLINICAL EFFECTS OF SMOKING AND CESSATION ON CANCER TREATMENT OUTCOMES
ADDRESSING TOBACCO USE BY THE CANCER PATIENT
RESEARCH CONSIDERATIONS AND THE FUTURE OF ADDRESSING TOBACCO USE ACROSS THE CONTINUUM OF CANCER CARE
Lifestyle Factors
INTRODUCTION
OBESITY
PHYSICAL ACTIVITY
NUTRITION
MECHANISTIC DATA
LIFESTYLE GUIDELINES FOR CANCER PREVENTION AND CONTROL
CONCLUSION
Genetic Counseling & Testing
THE ONCOLOGY GENETIC TESTING LANDSCAPE
THE EVOLVING ROLE OF GENETIC COUNSELORS
RESPONSIBLY SCALING GENETIC SERVICES
PRACTICAL GUIDANCE FOR ORDERING AND INTERPRETING GENETIC TESTING
ADDITIONAL ISSUES IN CANCER GENETIC COUNSELING
CONCLUSION
PART II Cancer Therapeutics
Essentials of Radiation Therapy
INTRODUCTION
RADIATION PHYSICS
TREATMENT PLANNING
OTHER TREATMENT MODALITIES
TREATMENT INTENT
FRACTIONATION
ADVERSE EFFECTS
PRINCIPLES OF THE USE OF AGENTS THAT MODIFY THE RADIATION RESPONSE
Alkylating Agents
HISTORICAL PERSPECTIVES
CHEMISTRY
CLASSIFICATION
CLINICAL PHARMACOKINETICS/ PHARMACODYNAMICS
THERAPEUTIC USES
TOXICITIES
COMPLICATIONS WITH HIGH-DOSE ALKYLATING AGENT THERAPY
ALKYLATING AGENT–STEROID CONJUGATES
DRUG RESISTANCE AND MODULATION
FUTURE PERSPECTIVES
PLATINUM COMPLEXES AFTER CISPLATIN
Platinum Analogs
INTRODUCTION
HISTORY
PLATINUM CHEMISTRY
MECHANISMS OF ACTION AND CELLULAR EFFECTS
COMBINATORIAL EFFORTS
CLINICAL PHARMACOLOGY
Antimetabolites
ANTIFOLATES
5-FLUOROPYRIMIDINES
CAPECITABINE
TRIFLURIDINE/TIPIRACIL
CYTARABINE
GEMCITABINE
6-THIOPURINES
FLUDARABINE
CLADRIBINE
CLOFARABINE
NELARABINE
Topoisomerase-Interacting Agents
BIOCHEMICAL AND BIOLOGICAL FUNCTIONS OF TOPOISOMERASES
TOPOISOMERASE INHIBITORS AS INTERFACIAL POISONS
TOPOISOMERASE I INHIBITORS: CAMPTOTHECINS AND BEYOND
TOPOISOMERASE II INHIBITORS: INTERCALATORS AND NONINTERCALATORS
TUMOR-TARGETED TOPOISOMERASE INHIBITORS
TOPOISOMERASE I INHIBITOR COMBINATIONS
DETERMINANTS OF RESPONSE TO TOPOISOMERASE INHIBITORS
Microtubule Inhibitors
MICROTUBULES
TAXANES
VINCA ALKALOIDS
MICROTUBULE ANTAGONISTS AND ADC PAYLOADS
ANTIMICROTUBULE PAYLOADS OF ANTIBODY DRUG CONJUGATES
MITOTIC MOTOR PROTEIN INHIBITORS
MECHANISMS OF RESISTANCE TO MICROTUBULE INHIBITORS
Kinase Inhibitors as Anticancer Drugs
INTRODUCTION
VALIDATING MUTATED KINASES AS CANCER DRUG TARGETS— THE DEVELOPMENT OF IMATINIB FOR PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AN
THE DEVELOPMENT OF HER2TARGETED THERAPIES IN BREAST AND OTHER CANCERS
THE DEVELOPMENT OF EGFR TYROSINE KINASE INHIBITORS IN LUNG CANCER
IDENTIFYING THERAPEUTIC TARGETS IN EGFR WILD-TYPE LUNG CANCERS
TARGETING BRAF-MUTANT TUMORS WITH RAF AND MEK INHIBITORS
PI3 KINASE PATHWAY INHIBITORS
FGFR INHIBITORS: AN IMPORTANT CASE FOR ISOFORM SELECTIVITY
ONE TARGET OR SEVERAL: MULTITARGETED KINASE INHIBITOR THERAPY
CDK4/6 INHIBITORS
BRUTON TYROSINE KINASE INHIBITORS—AN EXAMPLE OF LINEAGE DEPENDENCE
TUMOR AGNOSTIC DRUG TARGETS— TRK INHIBITORS FOR NTRK FUSION POSITIVE CANCERS
FUTURE DIRECTIONS
Histone Deacetylase Inhibitors, Demethylating Agents, and Epigenetic Drugs
INTRODUCTION
THE CANCER EPIGENOME
HISTONE DEACETYLASE INHIBITORS
OTHER EPIGENETIC DRUGS
Proteasome Inhibitors
BIOCHEMISTRY OF THE UBIQUITIN-PROTEASOME PATHWAY
PROTEASOME INHIBITORS
PROTEASOME INHIBITORS IN CANCER
AND
MUTATIONS AND DNA REPAIR
Poly(ADP-Ribose) Polymerase Inhibitors for Tumors with Defects in DNA Repair
INTRODUCTION
CELLULAR DNA REPAIR PATHWAYS
THE DEVELOPMENT OF PARP INHIBITORS
PARP-1 INHIBITION AS A SYNTHETIC LETHAL THERAPEUTIC STRATEGY FOR THE TREATMENT OF BRCA-DEFICIENT CANCERS
EARLY CLINICAL RESULTS TESTING SYNTHETIC LETHALITY OF PARP INHIBITORS AND
MUTATION
CLINICAL STUDIES LEADING TO THE APPROVAL OF PARP INHIBITORS FOR THERAPEUTIC USE
THE USE OF PARP INHIBITORS IN NON-
GERMLINE MUTANT CANCERS
MECHANISMS OF RESISTANCE TO PARP INHIBITORS
FUTURE PROSPECTS
DISCLOSURE
Miscellaneous Chemotherapeutic Agents
OMACETAXINE
MITOTANE
HYDROXYUREA
ARSENIC TRIOXIDE
BLEOMYCIN
MITOMYCIN-C
PROCARBAZINE
ASPARAGINASE
SIROLIMUS, TEMSIROLIMUS, EVEROLIMUS
THALIDOMIDE, LENALIDOMIDE, POMALIDOMIDE
MISCELLANEOUS AGENTS REPURPOSABLE FOR CANCER THERAPY
CARDIOVASCULAR DRUGS REPURPOSABLE FOR CANCER THERAPY
ANTIMICROBIAL DRUGS REPURPOSABLE FOR CANCER THERAPY
ANTIDIABETIC DRUGS REPURPOSABLE FOR CANCER THERAPY
Hormonal Agents
INTRODUCTION
SELECTIVE ESTROGEN RECEPTOR MODULATORS
AROMATASE INHIBITORS
RESISTANCE TO ENDOCRINE-TARGETED THERAPY IN BREAST CANCER
GONADOTROPIN-RELEASING HORMONE ANALOGS
ANTIANDROGENS
RESISTANCE TO ANDROGEN THERAPIES IN PROSTATE CANCER
OTHER SEX STEROID THERAPIES
OTHER HORMONAL THERAPIES
FACTORS REGULATING ANTIBODYBASED TUMOR TARGETING
Immunotherapy Agents: Monoclonal Antibodies
INTRODUCTION
IMMUNOGLOBULIN STRUCTURE
UNCONJUGATED ANTIBODY MECHANISMS OF ACTION
CONJUGATED ANTIBODIES
ANTIBODY MODIFICATIONS TO ENHANCE EFFICACY
ANTIBODIES APPROVED FOR USE IN SOLID TUMORS
ANTIBODIES APPROVED FOR USE IN HEMATOLOGIC MALIGNANCIES
CONCLUSION
EARLY STUDIES WITH CTLA-4 ANTIBODIES IN METASTATIC CANCER
Immunotherapy Agents: Checkpoint Modulators
INTRODUCTION
PRECLINICAL WORK WITH CTLA-4
ADJUVANT TRIALS OF IPI
PRECLINICAL WORK WITH PD-1
EARLY STUDIES WITH PD-1 ANTIBODIES IN METASTATIC CANCER
ADJUVANT TRIALS OF NIVOLUMAB AND PEMBROLIZUMAB
NEOADJUVANT TRIALS OF NIVOLUMAB AND PEMBROLIZUMAB IN MELANOMA AND OTHER CANCERS
IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
Immunotherapy Agents: Cellular Therapies
INTRODUCTION
TUMOR INFILTRATING LYMPHOCYTES (TIL)
CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS
T-CELL RECEPTOR ENGINEERED T CELLS (TCR)
OTHER POTENTIAL CELLULAR THERAPIES
IL-2 VARIANT MOLECULES— IMPROVING THE SAFETY AND EFFICACY OF HIGH-DOSE IL-2
Immunotherapy Agents: Nonspecific Stimulators
ROLE IN THE TUMOR MICROENVIRONMENT
ANTIBODY-CYTOKINE FUSION (IMMUNOCYTOKINES)
ONCOLYTIC VIRUSES
TALIMOGENE LAHERPAREPVEC
OTHER ONCOLYTIC VIRUSES
CLINICAL APPLICATION
TOLL-LIKE RECEPTOR AGONISTS
STING AGONISTS
T-CELL ACTIVATORS
4-1BB (CD137)
GITR (GLUCOCORTICOID-INDUCED TNF-R-RELATED PROTEIN)
ICOS (INDUCIBLE T-CELL COSTIMULATOR)
OX40
CD40
CYTOKINES OTHER THAN IL-2
Allogeneic Stem Cell Transplantation
INTRODUCTION
CONDITIONING REGIMENS
HEMATOPOIETIC STEM AND PROGENITOR CELL SOURCES
IMMUNOBIOLOGY OF TRANSPLANTATION
COMPLICATIONS OF ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR MANAGEMENT
GRAFT FAILURE
MAJOR DISEASE INDICATIONS FOR ALLOGENEIC STEM CELL TRANSPLANTATION
PREVENTION AND TREATMENT OF POSTTRANSPLANT RELAPSE
FUTURE DIRECTIONS
Index
9781975184681_WEB V2
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 2
Copyright
Contributing Authors
Preface
Acknowledgments
Contens
PART III Practice of Oncology
Design and Analysis of Clinical Trials
INTRODUCTION
PHASE I CLINICAL TRIALS
PHASE II CLINICAL TRIALS
DESIGN OF PHASE III CLINICAL TRIALS
FACTORIAL DESIGNS
ANALYSIS OF PHASE III CLINICAL TRIALS
REPORTING RESULTS OF CLINICAL TRIALS
FALSE-POSITIVE REPORTS IN THE LITERATURE
META-ANALYSIS
Section 1 Head and Neck
General Principles in the Management of Head and Neck Cancer
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
DIAGNOSIS
STAGING
PRINCIPLES OF TREATMENT FOR SQUAMOUS CELL CARCINOMA
MANAGEMENT
CLINICALLY NEGATIVE NECK
CLINICALLY POSITIVE NECK LYMPH NODES
CHEMOTHERAPY
Cancer of the Nasopharynx
EPIDEMIOLOGY AND ETIOLOGY
GENETIC RISK FACTORS AND PATHOGENETIC MECHANISMS
DIAGNOSTIC WORKUP AND SCREENING
STAGING
CLINICAL AND MOLECULAR BIOMARKERS
TREATMENT OF EARLY-STAGE DISEASE
TREATMENT OF LOCOREGIONALLY ADVANCED DISEASE
RADIOTHERAPY DELIVERY, PLANNING, AND DOSE FRACTIONATION
POST-TREATMENT SURVEILLANCE
TREATMENT OF RECURRENT OR METASTATIC DISEASE
Cancer of the Larynx and Hypopharynx
INTRODUCTION
LARYNX
HYPOPHARYNX: PHARYNGEAL WALLS, PYRIFORM SINUS, AND POSTCRICOID PHARYNX
Oropharynx Cancer
PATHOPHYSIOLOGY OF HPV-POSITIVE VERSUS HPV-NEGATIVE OPSCC
ANATOMY
WORKUP
STAGING
GENERAL PRINCIPLES FOR SELECTION OF TREATMENT
MANAGEMENT
MANAGEMENT OF RECURRENCE
CANCER SURVEILLANCE
SURVIVORSHIP
Cancer of the Oral Cavity
INTRODUCTION
EPIDEMIOLOGY
RISK FACTORS
WORKUP AND STAGING
LIP
FLOOR OF THE MOUTH
ORAL TONGUE
BUCCAL MUCOSA
GINGIVA AND HARD PALATE (INCLUDING RETROMOLAR TRIGONE)
NECK TREATMENT
Cancer of the Nasal Vestibule, Nasal Cavity, and Paranasal Sinuses
ANATOMY
PATHOLOGY
PATTERNS OF SPREAD
CLINICAL PICTURE
STAGING
TREATMENT
Cancer of the Salivary Gland
INTRODUCTION
ANATOMY
EPIDEMIOLOGY
CLINICAL PRESENTATION
DIAGNOSTIC WORKUP AND STAGING
STAGING
PATHOLOGICAL CLASSIFICATION
PROGNOSTIC FACTORS AND MOLECULAR MARKERS
TREATMENT
TREATMENT OUTCOMES
SURVEILLANCE AND SUVIVORSHIP
Section 2 Thoracic Cavity
Non–small-cell Lung Cancer
EPIDEMIOLOGY AND RISK FACTORS
CLINICAL MANIFESTATIONS, DIAGNOSIS, AND STAGING
PATHOLOGY
MOLECULAR LANDSCAPE OF NON–SMALL-CELL LUNG CANCER
TREATMENT OF PATIENTS WITH STAGE I TO III
TREATMENT OF STAGE IV
STAGE IV NON–SMALL-CELL LUNG CANCER WITHOUT DRIVER ALTERATIONS
OLIGOMETASTASES
MALIGNANT PLEURAL EFFUSION
CONCLUSION
Small Cell and Neuroendocrine Tumors of the Lung
INTRODUCTION
SMALL CELL LUNG CANCER
TYPICAL CARCINOID AND ATYPICAL CARCINOID TUMORS
LARGE CELL NEUROENDOCRINE CARCINOMA
Neoplasms of the Mediastinum
THYMIC NEOPLASMS
GERM CELL TUMORS
Index
9781975184681_WEB V3
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 3
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART III Practice of Oncology
Section 3 GI Tract
Cancer of the Esophagus
INTRODUCTION
EPIDEMIOLOGY
ETIOLOGIC FACTORS AND PREDISPOSING CONDITIONS
APPLIED ANATOMY AND HISTOLOGY
NATURAL HISTORY AND PATTERNS OF FAILURE
CLINICAL PRESENTATION
DIAGNOSTIC STUDIES AND PRETREATMENT STAGING TOOLS
STAGING GUIDELINES
BIOMARKERS
TREATMENT
PREDICTORS OF TREATMENT RESPONSE
PALLIATION OF ESOPHAGEAL CANCER WITH RADIATION THERAPY
RADIOTHERAPY TECHNIQUES
TREATMENT OF METASTATIC DISEASE
INCIDENCE AND EPIDEMIOLOGY
ETIOLOGY AND RISK FACTORS
Cancer of the Stomach
ANATOMIC CONSIDERATIONS
PATTERNS OF SPREAD
HISTOPATHOLOGY
MOLECULAR CLASSIFICATION
CLINICAL PRESENTATION
PRETREATMENT EVALUATION
STAGING
LOCALIZED DISEASE
ADJUVANT AND NEOADJUVANT THERAPY
TREATMENT OF ADVANCED DISEASE (STAGE IV)
GASTRIC CANCER IN THE ELDERLY
PALLIATIVE MEASURES FOR ADVANCED DISEASE
Cancer of the Pancreas
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
EXOCRINE PANCREATIC CANCERS
ENDOCRINE PANCREATIC CANCERS
PANCREATIC DUCTAL ADENOCARCINOMA: SCREENING
PANCREATIC DUCTAL ADENOCARCINOMA: DIAGNOSIS
PANCREATIC DUCTAL ADENOCARCINOMA: STAGING AND ASSESSMENT OF RESECTABILITY
CLINICALLY RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
CLINICALLY BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
CLINICALLY LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
STAGE IV: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
FUTURE DIRECTIONS AND CHALLENGES
CONCLUSIONS
Cancer of the Liver
INTRODUCTION
EPIDEMIOLOGY
ETIOLOGIC FACTORS
DIAGNOSIS
STAGING
MOLECULAR AND BIOMARKER
TREATMENT OF HEPATOCELLULAR CARCINOMA
ADJUVANT AND NEOADJUVANT THERAPY
TREATMENT OF OTHER PRIMARY LIVER TUMORS
Cancer of the Biliary Tree
INTRODUCTION
ANATOMY OF THE BILIARY TRACT
CHOLANGIOCARCINOMA
GALLBLADDER CANCER
SYSTEMIC THERAPY FOR CHOLANGIOCARCINOMA
Small Bowel Cancer
INTRODUCTION
SMALL BOWEL ADENOCARCINOMA
CARCINOID TUMORS
SMALL BOWEL LYMPHOMA
GASTROINTESTINAL STROMAL TUMOR
METASTATIC CANCER TO THE SMALL BOWEL
ANATOMY AND PATHOLOGY
Gastrointestinal Stromal Tumor
INTRODUCTION
INCIDENCE AND ETIOLOGY
SCREENING
DIAGNOSIS
STAGING
MANAGEMENT BY STAGE
PALLIATIVE CARE
Cancer of the Colon
INTRODUCTION
MOLECULAR BIOLOGY
MULTISTEP MODELS OF COLORECTAL CANCER AND GENETIC INSTABILITY
MUTATIONAL AND EPIGENETIC LANDSCAPES IN COLORECTAL CANCER
ONCOGENE AND TUMOR SUPPRESSOR GENE MUTATIONS IN COLORECTAL CANCER PROGRESSION
EPIDEMIOLOGY
ETIOLOGY: GENETIC AND ENVIRONMENTAL RISK FACTORS
FAMILIAL COLORECTAL CANCER
ANATOMY OF THE COLON
DIAGNOSIS OF COLORECTAL CANCER
SCREENING FOR COLORECTAL CANCER
STAGING AND PROGNOSIS OF COLORECTAL CANCER
APPROACHES TO SURGICAL RESECTION OF COLON CANCER
SURGICAL MANAGEMENT OF COMPLICATIONS FROM PRIMARY COLON CANCER
LAPAROSCOPIC COLON RESECTION
POLYPS AND STAGE I COLON CANCER
STAGE II AND STAGE III COLON CANCER
TREATMENT OF STAGE II PATIENTS
TREATMENT OPTIONS FOR STAGE III PATIENTS
INVESTIGATIONAL ADJUVANT APPROACHES
FOLLOW-UP AFTER MANAGEMENT OF COLON CANCER WITH CURATIVE INTENT
SURGICAL MANAGEMENT OF STAGE IV DISEASE
MANAGEMENT OF UNRESECTABLE METASTATIC DISEASE
MOLECULAR PREDICTIVE MARKERS
Cancer of the Rectum
INTRODUCTION
ANATOMY
STAGING
SURGERY
DOES ADJUVANT RADIATION THERAPY IMPACT SURVIVAL?
PREOPERATIVE RADIATION THERAPY
WHICH PATIENTS SHOULD RECEIVE ADJUVANT THERAPY?
SUPPORT OF NONOPERATIVE MANAGEMENT
TOTAL NEOADJUVANT THERAPY
CONCURRENT CHEMOTHERAPY
SYNCHRONOUS RECTAL PRIMARY AND METASTASES
MANAGEMENT OF UNRESECTABLE PRIMARY AND LOCALLY ADVANCED DISEASE (T4)
MANAGEMENT OF LOCALLY RECURRENT DISEASE
RE-IRRADIATION IN RECURRENT DISEASE
RADIATION THERAPY TECHNIQUE
RADIATION FIELDS
Cancer of the Anal Region
INTRODUCTION
EPIDEMIOLOGY AND ETIOLOGY
SCREENING AND PREVENTION
CLINICAL PRESENTATION AND STAGING
PROGNOSTIC FACTORS
TREATMENT OF LOCALIZED SQUAMOUS CELL CARCINOMA
TREATMENT OF OTHER SITES AND PATHOLOGIES
Index
9781975184681_WEB V4
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 4
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART III Practice of Oncology
Section 4 Cancers of the GU Tract
Cancer of the Kidney
INTRODUCTION
EPIDEMIOLOGY, DEMOGRAPHICS, AND RISK FACTORS
PATHOLOGY OF RENAL CELL CARCINOMA
DIFFERENTIAL DIAGNOSIS AND STAGING
HEREDITARY KIDNEY CANCER SYNDROMES, GENETICS, AND MOLECULAR BIOLOGY
TREATMENT OF LOCALIZED RENAL CELL CARCINOMA
TREATMENT OF LOCALLY ADVANCED RENAL CELL CARCINOMA
SURGICAL MANAGEMENT OF ADVANCED RENAL CELL CARCINOMA
SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA
CONCLUSION AND FUTURE DIRECTIONS
ACKNOWLEDGMENTS
SCREENING AND EARLY DETECTION
INTRODUCTION
EPIDEMIOLOGY
Cancer of the Bladder, Ureter, and Renal Pelvis
PATHOLOGY
MOLECULAR BIOLOGY OF BLADDER CANCER AND BIOMARKERS
CANCER OF THE BLADDER
CANCERS OF THE RENAL PELVIS AND URETER
Cancer of the Prostate
INTRODUCTION
EPIDEMIOLOGY
ANATOMY AND PATHOLOGY
SCREENING
DIAGNOSIS AND WORKUP
RISK STRATIFICATION
TREATMENT OF PROSTATE CANCER
MANAGEMENT OF CLINICAL DISEASE STATES
FUTURE DIRECTIONS
Cancer of the Urethra and Penis
INTRODUCTION
URETHRAL CANCER IN MEN
URETHRAL CANCER IN THE FEMALE
PENILE CANCER
Cancer of the Testis
INTRODUCTION
INCIDENCE AND EPIDEMIOLOGY
INITIAL PRESENTATION AND MANAGEMENT
HISTOLOGY
BIOLOGY
IMMUNOHISTOCHEMICAL MARKERS
STAGING
MANAGEMENT OF CLINICAL STAGE I DISEASE
MANAGEMENT OF CLINICAL STAGE II DISEASE (LOW TUMOR BURDEN)
MANAGEMENT OF STAGE II DISEASE WITH HIGH TUMOR BURDEN AND STAGE III DISEASE
MANAGEMENT OF RECURRENT DISEASE
TREATMENT SEQUELAE
LONG-TERM FOLLOW-UP
MIDLINE TUMORS OF UNCERTAIN HISTOGENESIS
OTHER TESTICULAR TUMORS
Section 5 Gynecological Cancers
Cancer of the Cervix
EPIDEMIOLOGY
PREVENTION
PATHOLOGY
CLINICAL MANIFESTATIONS
CLINICAL EVALUATION AND STAGING
PROGNOSTIC FACTORS
CHEMOTHERAPY FOLLOWED BY RADICAL SURGERY
MANAGEMENT OF ABNORMAL CERVICAL SCREENING
TREATMENT OF INVASIVE DISEASE
Cancer of the Vagina and Vulva
CARCINOMA OF THE VAGINA
CARCINOMA OF THE VULVA
Cancer of the Uterine Body
ENDOMETRIAL CARCINOMA
UTERINE SARCOMAS
INDICATIONS FOR TREATMENT
Gestational Trophoblastic Neoplasia
INTRODUCTION
INCIDENCE
GENETICS, PATHOLOGY, AND NATURAL HISTORY
MEASUREMENT OF HUMAN CHORIONIC GONADOTROPIN
PRETREATMENT EVALUATION
STAGING AND PROGNOSTIC SCORE
TREATMENT
PLACENTAL SITE OR EPITHELIOID TROPHOBLASTIC TUMORS
SUBSEQUENT PREGNANCY AFTER TREATMENT FOR GESTATIONAL TROPHOBLASTIC NEOPLASIA
Ovarian Cancer
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
SCREENING AND PREVENTION
DIAGNOSIS
PRESENTATION AND EVALUATION OF ADVANCED DISEASE
INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING
MANAGEMENT BY STAGE
MANAGEMENT OF NEWLY DIAGNOSED ADVANCED-STAGE DISEASE
MAINTENANCE TARGETED THERAPY
MAINTENANCE THERAPY USING PARP INHIBITORS
CLINICAL IMPLICATIONS OF
MUTATION STATUS
REVERSION MUTATIONS
TOLERABILITY OF PARP INHIBITORS
MANAGEMENT OF RECURRENT DISEASE
ANTIANGIOGENESIS THERAPY FOR TREATMENT OF RECURRENT DISEASE
IMMUNOTHERAPY
RANDOMIZED TRIALS OF IMMUNE CHECKPOINT INHIBITORS
THERAPEUTIC VACCINES
TOLL-LIKE RECEPTORS
ONCOLYTIC VIRUSES
CHIMERIC ANTIGEN RECEPTORS
BISPECIFIC T-CELL ENGAGERS
IMMUNE-MEDIATED TOXICITY
IMMUNE-RELATED RESPONSE CRITERIA
PALLIATIVE CARE
Section 6 Breast Cancer
Malignant Tumors of the Breast
INCIDENCE AND ETIOLOGY
SCREENING AND PREVENTION FOR WOMEN AT HIGH RISK OF BREAST CANCER
ANATOMY AND PATHOLOGY
DIAGNOSIS AND BIOPSY
STAGING
MANAGEMENT BY STAGE: DUCTAL CARCINOMA IN SITU
MANAGEMENT BY STAGE: PRIMARY OPERABLE INVASIVE BREAST CANCER
MANAGEMENT BY STAGE: ADJUVANT SYSTEMIC THERAPY
MANAGEMENT BY STAGE: SPECIAL CONSIDERATIONS
MANAGEMENT BY STAGE: METASTATIC DISEASE
ACKNOWLEDGMENT
Index
9781975184681_WEB V5
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 5
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART III Practice of Oncology
Section 7 Cancer of the Endocrine System
Thyroid Tumors
THYROID NODULES
ANATOMY AND PHYSIOLOGY
THYROID TUMOR CLASSIFICATION AND STAGING SYSTEMS
DIFFERENTIATED THYROID CANCER
TREATMENT OF DIFFERENTIATED THYROID CANCER
ANAPLASTIC THYROID CANCER
MEDULLARY THYROID CANCER
THYROID LYMPHOMA
THYROID CANCER IN CHILDREN
Parathyroid Tumors
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
CLINICAL MANIFESTATIONS AND SCREENING
DIAGNOSIS
STAGING
MANAGEMENT OF PARATHYROID CARCINOMA
FOLLOW-UP AND NATURAL HISTORY
PROGNOSIS
Adrenal Tumors
INTRODUCTION
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
SCREENING
DIAGNOSIS
STAGING
MANAGEMENT
PALLIATIVE CARE
Pancreatic Neuroendocrine Neoplasms
INTRODUCTION
INCIDENCE AND ETIOLOGY
CLASSIFICATION, HISTOPATHOLOGY, AND MOLECULAR GENETICS
DIAGNOSIS AND MANAGEMENT OF PANCREATIC NEUROENDOCRINE TUMORS
FUNCTIONAL TUMORS
ADDITIONAL CLINICAL CONSIDERATIONS
SMALL NONFUNCTIONING SPORADIC PANCREATIC NEUROENDOCRINE TUMORS
Carcinoid Tumors and the Carcinoid Syndrome
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
GENERAL PRINCIPLES OF DIAGNOSIS AND STAGING
GENERAL MANAGEMENT PRINCIPLES
DIAGNOSIS, STAGING, AND MANAGEMENT BY PRIMARY TUMOR SITE
DIAGNOSIS AND MANAGEMENT OF CARCINOID SYNDROME
MEDICAL MANAGEMENT OF NETS
MANAGEMENT OF GI NET LIVER METASTASES
CONCLUSIONS
Multiple Endocrine Neoplasia
INTRODUCTION
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1
MULTIPLE ENDOCRINE NEOPLASIA TYPES 2 AND 3 AND FAMILIAL MEDULLARY THYROID CANCER
MULTIPLE ENDOCRINE NEOPLASIA TYPE 4
Section 8 Sarcomas and Soft Tissue
Soft Tissue Sarcoma
INTRODUCTION
INCIDENCE AND ETIOLOGY
ANATOMIC AND AGE DISTRIBUTION AND PATHOLOGY
CLINICAL AND PATHOLOGIC FEATURES OF SPECIFIC SOFT TISSUE TUMOR TYPES
DIAGNOSIS AND STAGING
MANAGEMENT BY PRESENTATION STATUS, EXTENT OF DISEASE, AND ANATOMIC LOCATION
FUTURE DIRECTIONS
INTRODUCTION
Sarcomas of Bone
ANATOMY AND PATHOLOGY
INCIDENCE AND ETIOLOGY
MOLECULAR BIOLOGY: DIAGNOSTICS AND BIOMARKERS
SCREENING
DIAGNOSIS
STAGING
MANAGEMENT BY DIAGNOSIS AND STAGE
CONTINUING CARE: SURVEILLANCE AND PALLIATION
Section 9 Cancers of the Skin
Cancer of the Skin
GENERAL
BASAL CELL CARCINOMA
SQUAMOUS CELL CARCINOMA AND ACTINIC KERATOSIS
MERKEL CELL CARCINOMA
DERMATOFIBROSARCOMA PROTUBERANS
ANGIOSARCOMA
MICROCYSTIC ADNEXAL CARCINOMA
SEBACEOUS CARCINOMA
EXTRAMAMMARY PAGET DISEASE
ATYPICAL FIBROXANTHOMA AND PLEOMORPHIC DERMAL SARCOMA
Cutaneous Melanoma
INTRODUCTION
CLASSIFICATION OF MELANOMA SUBTYPES
MOLECULAR BIOLOGY OF MELANOMA
EPIDEMIOLOGY
CHANGES IN INCIDENCE
SEX AND AGE DISTRIBUTION
MELANOMA IN CHILDREN, INFANTS, AND NEONATES
ANATOMIC DISTRIBUTION
ETIOLOGY AND RISK FACTORS
PREVENTION AND SCREENING
DIAGNOSIS OF PRIMARY MELANOMA
GENERAL CONSIDERATIONS IN CLINICAL MANAGEMENT OF A NEWLY DIAGNOSED CUTANEOUS MELANOMA (STAGES I AND II)
CLINICAL TRIALS TO DEFINE MARGINS OF EXCISION FOR PRIMARY CUTANEOUS MELANOMAS
SURGICAL STAGING OF REGIONAL NODES
SELECTION OF PATIENTS FOR SENTINEL NODE BIOPSY
MANAGEMENT OF CLINICALLY LOCALIZED MELANOMA
THICK MELANOMAS
SPECIAL CONSIDERATIONS IN MANAGEMENT OF PRIMARY MELANOMAS
RADIOTHERAPY FOR A PRIMARY MELANOMA
CLINICAL FOLLOW-UP FOR INTERMEDIATE-THICKNESS AND THICK MELANOMAS (STAGE IB TO IIC)
REGIONALLY METASTATIC MELANOMA (STAGE III): LYMPH NODE METASTASIS, SATELLITE LESIONS, AND IN-TRANSIT METASTASES
ADJUVANT LYMPH NODE BASIN RADIOTHERAPY
NEOADJVUANT THERAPY IN MELANOMA
ADJUVANT SYSTEMIC THERAPY FOR STAGE III-IV AFTER SURGICAL RESECTION
MANAGEMENT OF DISTANT METASTASES OF MELANOMA (STAGE IV)
RADIATION THERAPY FOR OLIGOMETASTATIC MELANOMA
Section 10 CNS
Neoplasms of the Central Nervous System
EPIDEMIOLOGY OF BRAIN TUMORS
CLASSIFICATION AND PATHOLOGY
CLINICAL CONSIDERATIONS BY ANATOMIC LOCATION
NEURODIAGNOSTIC TESTS AND IMAGING
SURGERY
RADIATION THERAPY
SYSTEMIC TREATMENTS (CYTOTOXIC CHEMOTHERAPY, TARGETED AGENTS, AND IMMUNOTHERAPY)
SPECIFIC CENTRAL NERVOUS SYSTEM NEOPLASMS
GLIOMATOSIS CEREBRI
OPTIC, CHIASMAL, AND HYPOTHALAMIC GLIOMAS
BRAIN STEM GLIOMAS
CEREBELLAR ASTROCYTOMAS
GANGLIOGLIOMAS
EPENDYMOMA
MENINGIOMAS
PRIMITIVE NEUROECTODERMAL OR EMBRYONAL CENTRAL NERVOUS SYSTEM NEOPLASMS
PINEAL REGION TUMORS AND GERM CELL TUMORS
PITUITARY ADENOMAS
CRANIOPHARYNGIOMAS
VESTIBULAR SCHWANNOMAS
GLOMUS JUGULARE TUMORS
HEMANGIOBLASTOMAS
CHORDOMAS AND CHONDROSARCOMAS
CHOROID PLEXUS TUMORS
SPINAL AXIS TUMORS
Index
9781975184681_WEB V6
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 6
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART III Practice of Oncology
Section 11 Cancers in Adolescents and Young Adults
Adolescents and Young Adults with Cancer
INTRODUCTION
EPIDEMIOLOGY
ETIOLOGY AND BIOLOGY
SIGNS, SYMPTOMS, AND DELAYS IN DIAGNOSIS
PREVENTION AND SCREENING
DIAGNOSIS
MANAGEMENT
PROGRESS
FUTURE CHALLENGES
Section 12 Lymphomas in Adults
Hodgkin Lymphoma
INTRODUCTION
ETIOLOGY
PATHOLOGY OF HODGKIN LYMPHOMA
STAGING
EARLY-STAGE HODGKIN LYMPHOMA
ADVANCED-STAGE HODGKIN LYMPHOMA
SPECIAL CIRCUMSTANCES
Non-Hodgkin Lymphoma
INTRODUCTION
INCIDENCE AND ETIOLOGY
LYMPHOMA CLASSIFICATION: THE PRINCIPLES OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF LYMPHOID NEOPLASMS
DIFFERENTIAL DIAGNOSIS AND SITES OF DISEASE AT PRESENTATION
INITIAL MANAGEMENT
STAGING AND PROGNOSTIC SYSTEMS
SPECIFIC DISEASE ENTITIES
MATURE T-CELL AND NATURAL KILLER CELL NEOPLASMS
Cutaneous Lymphomas
INTRODUCTION
MYCOSIS FUNGOIDES AND THE SÉZARY SYNDROME
EPIDEMIOLOGY AND ETIOLOGY
PATHOBIOLOGY
DIAGNOSIS AND STAGING
THE SÉZARY SYNDROME
STAGING AND PROGNOSIS OF MYCOSIS FUNGOIDES AND THE SÉZARY SYNDROME
CLINICAL EVALUATION OF PATIENTS WITH CUTANEOUS LYMPHOMA
PRINCIPLES OF THERAPY OF MYCOSIS FUNGOIDES AND THE SÉZARY SYNDROME
SKIN-DIRECTED THERAPY
SYSTEMIC THERAPY FOR MYCOSIS FUNGOIDES AND THE SÉZARY SYNDROME
OTHER CUTANEOUS LYMPHOMAS
Primary Central Nervous System Lymphoma
DEFINITION AND EPIDEMIOLOGY
HISTOPATHOLOGY AND MOLECULAR PROFILE
DIAGNOSIS AND EVALUATION
PROGNOSTIC MODELS
STEROIDS AND SURGERY
TREATMENT OF NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
MANAGEMENT OF REFRACTORY/ RELAPSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
PRIMARY VITREORETINAL LYMPHOMA
MONITORING AND FOLLOW-UP
NEUROTOXICITY
Section 13 Leukemias and Plasma Cell Tumors
Management of Acute Leukemias
INTRODUCTION
ACUTE MYELOID LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA
Chronic Myeloid Leukemia
INTRODUCTION
EPIDEMIOLOGY AND PATHOGENESIS
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS, STAGING, AND PROGNOSTIC FACTORS
PROGNOSTIC FACTORS
THERAPY
ASSESSMENT OF RESPONSE TO TYROSINE KINASE INHIBITORS
THERAPY OF THE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
TREATMENT OF ADVANCED DISEASE
FUTURE DIRECTIONS
Chronic Lymphocytic Leukemias
INTRODUCTION
IMMUNOPHENOTYPE
MOLECULAR BIOLOGY
IMMUNE ABNORMALITIES
DIAGNOSIS
CLINICAL MANIFESTATIONS
LABORATORY FINDINGS
STAGING
INDICATIONS FOR TREATMENT AND RESPONSE CRITERIA
TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA
MANAGEMENT CONSIDERATIONS AND RECOMMENDATIONS
PROLYMPHOCYTIC LEUKEMIA
LARGE GRANULAR LYMPHOCYTE LEUKEMIA
HAIRY CELL LEUKEMIA
Myelodysplastic Syndromes
INTRODUCTION
HISTORICAL PERSPECTIVE
EPIDEMIOLOGY
PATHOGENESIS
ETIOLOGY
CLINICAL PRESENTATION
DIAGNOSIS
SUBTYPES OF MYELODYSPLASTIC SYNDROMES AND CLASSIFICATION
RISK STRATIFICATION AND SURVIVAL
MANAGEMENT
FUTURE PERSPECTIVE
CONCLUSION
Plasma Cell Neoplasms
INTRODUCTION
MULTIPLE MYELOMA
PATHOGENESIS
CYTOGENETIC CLASSIFICATION
CLINICAL FEATURES
DIAGNOSTIC TESTS
DIFFERENTIAL DIAGNOSIS
STAGING AND RISK STRATIFICATION
PROGNOSIS
TREATMENT
SUPPORTIVE CARE
INTRODUCTION
INCIDENCE AND PREVALENCE
CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
PROGNOSIS
RISK STRATIFICATION
MANAGEMENT
INTRODUCTION
PREVALENCE
CLINICAL FEATURES
DIFFERENTIAL DIAGNOSIS
PROGNOSIS
RISK STRATIFICATION
MANAGEMENT
SYSTEMIC AL (IMMUNOGLOBULIN LIGHT CHAIN) AMYLOIDOSIS
DIAGNOSIS
PROGNOSIS
TREATMENT
SOLITARY PLASMACYTOMA
DIAGNOSIS AND PROGNOSIS
TREATMENT
POEMS SYNDROME
Section 14 Other Cancers
Cancer of Unknown Primary
INTRODUCTION
PATHOLOGY EVALUATION
ADDITIONAL DIAGNOSTIC TESTS IN CANCER OF UNKNOWN PRIMARY
USE OF NEXT-GENERATION SEQUENCING
CLINICAL FEATURES AND EVALUATION
TREATMENT
PROGNOSTIC FACTORS
Benign and Malignant Mesothelioma
EPIDEMIOLOGY
DIAGNOSIS AND EVALUATION
PROGNOSTICATION OF MPM TO GUIDE CLINICAL MANAGEMENT
TREATMENT
Peritoneal Metastases and Peritoneal Mesothelioma
INTRODUCTION
NATURAL HISTORY OF PERITONEAL METASTASES
TREATMENT OPTIONS BASED ON NATURAL HISTORY AND PHARMACOLOGIC STUDIES
SELECTION OF TREATMENT USING QUANTITATIVE PROGNOSTIC INDICATORS
TREATMENT OF APPENDICEAL MALIGNANCY WITH PERITONEAL METASTASES
CURATIVE TREATMENT AND PREVENTION OF COLORECTAL PERITONEAL METASTASES
PREVENTION AND TREATMENT OF GASTRIC CANCER PERITONEAL METASTASES
TREATMENT OF OVARIAN CANCER PERITONEAL METASTASES
MANAGEMENT OF PERITONEAL MESOTHELIOMA
Intraocular Melanoma
INTRODUCTION
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOLOGY
OPHTHALMIC DIAGNOSIS
UNIVERSAL UVEAL MELANOMA STAGING
MANAGEMENT OF PRIMARY UVEAL MELANOMA
OVERVIEW: TREATMENT OF CHOROIDAL MELANOMA
TREATMENT FOR SPECIAL CASES
DIAGNOSIS OF METASTASIS
BIOMARKERS: PROGNOSTIC AND PREDICTIVE FACTORS
SUMMARY
Index
9781975184681_WEB V7
DeVita, Hellman & Rosenberg's Cancer: Principles and Practice of Oncology 12e Volume 7
Copyright
Contributing Authors
Preface
Acknowledgments
Contents
PART III Practice of Oncology
Section 15 Oncologic Emergencies
Superior Vena Cava Syndrome
INTRODUCTION
ANATOMY AND PATHOPHYSIOLOGY
CLINICAL PRESENTATION AND ETIOLOGY
DIAGNOSTIC WORKUP
DISEASE-SPECIFIC MANAGEMENT AND OUTCOMES
SMALL-CELL LUNG CANCER
NON–SMALL-CELL LUNG CANCER
NON-HODGKIN LYMPHOMA
NONMALIGNANT CAUSES
CATHETER-INDUCED OBSTRUCTION
TREATMENT
AREAS OF UNCERTAINTY
RECOMMENDATIONS
Increased Intracranial Pressure
INTRODUCTION
PATHOPHYSIOLOGIC CONSIDERATIONS
EPIDEMIOLOGY AND PATHOGENESIS
CLINICAL PRESENTATION
DIAGNOSIS
TREATMENT
Spinal Cord Compression
INCIDENCE AND ETIOLOGY
ANATOMY AND PATHOPHYSIOLOGY
CLINICAL PRESENTATION
DIFFERENTIAL DIAGNOSIS
DIAGNOSIS
GRADING
MANAGEMENT BY STAGE
Metabolic Emergencies
INTRODUCTION
TUMOR LYSIS SYNDROME AND HYPERURICEMIA
HYPONATREMIA
HYPERCALCEMIA
LACTIC ACIDOSIS
HYPERAMMONEMIA
Section 16 Treatment of Metastatic Cancer
Metastatic Cancer to the Brain
INTRODUCTION
EPIDEMIOLOGY
CLINICAL PRESENTATION
IMAGING AND DIAGNOSIS
PROGNOSIS
SYMPTOM MANAGEMENT
TREATMENT OPTIONS
LEPTOMENINGEAL METASTASES
FOLLOW-UP AND IMAGING
Metastatic Cancer to the Lungs
INTRODUCTION
PRESENTATION AND DIAGNOSIS OF PULMONARY METASTASES
SURGICAL METASTASECTOMY
ABLATIVE THERAPIES
TREATMENT CONCERNS AND OUTCOMES FOR INDIVIDUAL HISTOLOGIES
CONCLUSION
Metastatic Cancer to the Liver
INTRODUCTION
HEPATIC COLORECTAL ADENOCARCINOMA METASTASES
HEPATIC NEUROENDOCRINE CARCINOMA METASTASES
NONCOLORECTAL NONNEUROENDOCRINE HEPATIC METASTASES
Metastatic Cancer to the Bone
INTRODUCTION
PRESENTATION
PATHOPHYSIOLOGY
DIAGNOSTIC EVALUATION
OPTIMUM USE OF BONE-TARGETED AGENTS IN METASTATIC BONE DISEASE
NEW TARGETED THERAPIES IN THE TREATMENT OF METASTATIC BONE DISEASE
EXTERNAL-BEAM RADIATION THERAPY
SYSTEMIC RADIONUCLIDES
RADIOTHERAPY FOR COMPLICATED BONE METASTASES: LOCALIZED EXTERNAL BEAM
Malignant Pleural and Pericardial Effusions
MALIGNANT PLEURAL EFFUSIONS
TREATMENT ALGORITHM
MALIGNANT PERICARDIAL EFFUSIONS
CONCLUSION
Malignant Ascites
INCIDENCE AND ETIOLOGY
FLUID REGULATION AND PATHOPHYSIOLOGY
DIAGNOSIS
MANAGEMENT
Paraneoplastic Syndromes
INTRODUCTION
PARANEOPLASTIC NEUROLOGIC SYNDROMES
PARANEOPLASTIC ENDOCRINOLOGY SYNDROMES
PARANEOPLASTIC HEMATOLOGIC SYNDROMES
PARANEOPLASTIC DERMATOLOGIC MANIFESTATIONS
PARANEOPLASTIC RHEUMATOLOGIC MANIFESTATIONS
Section 17 Management of Adverse Effects of Treatment
Neutropenia and Thrombocytopenia
INTRODUCTION
Nausea and Vomiting
INTRODUCTION
NAUSEA AND VOMITING SYNDROMES
PATHOPHYSIOLOGY OF TREATMENTINDUCED NAUSEA AND VOMITING
DEFINING THE RISK OF NAUSEA AND VOMITING
ANTIEMETIC AGENTS
LOWER THERAPEUTIC INDEX
ANTIEMETIC TREATMENT BY CLINICAL SETTING
SPECIAL CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING PROBLEMS
RADIOTHERAPY-INDUCED NAUSEA AND VOMITING
Diarrhea and Constipation
INTRODUCTION
DIARRHEA
NEUTROPENIC COLITIS
ISCHEMIC COLITIS (NON-NEUTROPENIC ENTEROCOLITIS)
TARGETED THERAPY–ASSOCIATED DIARRHEA
IMMUNOTHERAPY-ASSOCIATED DIARRHEA
RADIOTHERAPY-INDUCED DIARRHEA
OTHER CAUSES OF TREATMENTRELATED DIARRHEA
ASSESSMENT
GENERAL PRINCIPLES IN THE MANAGEMENT OF DIARRHEA
ANTIDIARRHEAL MEDICATIONS
SPECIFIC MANAGEMENT GUIDELINES
RADIATION THERAPY–INDUCED DIARRHEA
IMMUNOTHERAPY-INDUCED DIARRHEA AND COLITIS
MANAGEMENT OF NEUTROPENIC ENTEROCOLITIS
DIARRHEA PROPHYLAXIS
CONSTIPATION
CONCLUSION
Oral Complications
INTRODUCTION
ORAL MUCOSITIS
RADIATION THERAPY–RELATED COMPLICATIONS
PATHOGENESIS OF CHEMOTHERAPYAND RADIATION THERAPY-INDUCED ORAL MUCOSITIS
CHRONIC GRAFT-VERSUS-HOST DISEASE ORAL MANIFESTATIONS
SEQUELAE OF ORAL COMPLICATIONS
STRATEGIES FOR PREVENTION AND TREATMENT OF ORAL COMPLICATIONS
TREATMENT STRATEGIES
RADIOPROTECTORS
BIOLOGIC RESPONSE MODIFIERS
TREATMENT FOR ORAL CHRONIC GRAFT-VERSUS-HOST DISEASE
SYMPTOM MANAGEMENT
Cardiac Toxicity
INTRODUCTION
CARDIOMYOPATHY AND CONGESTIVE HEART FAILURE
PRETREATMENT EVALUATION
SURVEILLANCE BEFORE, DURING, AND AFTER TREATMENT
CARDIOPROTECTIVE PHARMACOTHERAPY
STRESS CARDIOMYOPATHY (TAKOTSUBO CARDIOMYOPATHY)
ISCHEMIC HEART DISEASE
AGENTS ASSOCIATED WITH METABOLIC ABNORMALITIES
CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL AND ACCELERATED ATHEROSCLEROSIS
MANAGEMENT OF ISCHEMIC CARDIAC EVENTS DURING CHEMOTHERAPY
ARRYTHMIA AND LONG QTC SYNDROME
IMMUNOTHERAPIES, MYOCARDITIS, PERICARDITIS, AND CYTOKINE RELEASE
RADIATION-ASSOCIATED CARDIOVASCULAR DISEASE
MANAGEMENT AND LONG-TERM SURVEILLANCE
Gonadal Dysfunction
INTRODUCTION
EFFECTS OF CYTOTOXIC AGENTS ON ADULT MEN
EFFECTS OF CYTOTOXIC AGENTS ON ADULT WOMEN
EFFECTS OF CYTOTOXIC AGENTS ON CHILDREN
GONADAL DYSFUNCTION AFTER CRANIAL IRRADIATION
PRESERVATION OF FERTILITY, HORMONE LEVELS, AND SEXUAL FUNCTION
GENETIC CONCERNS
ACKNOWLEDGMENTS
Fatigue
INTRODUCTION
DEFINITION, RISK FACTORS, AND MECHANISMS OF CANCER-RELATED FATIGUE
SCREENING AND EVALUATION OF THE PATIENT WITH CANCER-RELATED FATIGUE
INTERVENTIONS FOR CANCER-RELATED FATIGUE
PHARMACOLOGIC INTERVENTIONS
NONPHARMACOLOGIC INTERVENTIONS
COMPLEMENTARY AND INTEGRATIVE THERAPIES
SUMMARY
Neurocognitive Effects
INTRODUCTION
ASSESSMENT AND CLINICAL SIGNIFICANCE OF NEUROCOGNITIVE FUNCTION IMPAIRMENT
INCIDENCE OF CANCER-RELATED COGNITIVE DYSFUNCTION
INCIDENCE AND MECHANISMS OF LOCAL CANCER THERAPY-RELATED COGNITIVE DYSFUNCTION
INCIDENCE AND MECHANISMS OF SYSTEMIC CANCER THERAPY-RELATED COGNITIVE DYSFUNCTION
STRATEGIES TO MITIGATE NEUROCOGNITIVE EFFECTS OF CANCER THERAPY
CONCLUSION
Management of Cancer Pain
INTRODUCTION
ASSESSMENT
MANAGEMENT
SPECIAL POPULATIONS
CONCLUSION
ACKNOWLEDGMENT
Nutrition Support
BACKGROUND
CAUSES OF MALNUTRITION IN CANCER PATIENTS
CANCER CACHEXIA SYNDROME (CCS)
NUTRITION SCREENING AND ASSESSMENT
PHARMACOTHERAPY OF CANCER-ASSOCIATED WEIGHT LOSS AND MALNUTRITION
NUTRITION SUPPORT OF CANCER PATIENTS
Sexual Problems
INTRODUCTION
CANCER IN MEN
CANCERS THAT AFFECT MEN AND WOMEN
CANCER IN WOMEN
ADOLESCENT AND YOUNG ADULT CANCER SURVIVORS
RELEVANT SOCIOCULTURAL CONSIDERATIONS
DISRUPTION OF INTIMACY AND RELATIONAL CONSIDERATIONS
COMMUNICATION ABOUT SEXUAL PROBLEMS
Psychiatric Distress and Resilience
INTRODUCTION
COMMON PSYCHIATRIC CONDITIONS
SCREENING FOR PSYCHOLOGICAL PROBLEMS
COPING
TREATMENT INTERVENTIONS
PSYCHOACTIVE AND PSYCHOTROPIC MEDICATIONS
CONCLUSION
How We Talk to Patients and How We Talk to Ourselves
INTRODUCTION
ORGANIZING THOUGHTS FOR DISCUSSION AND TREATMENT
THE POTENTIAL FOR CURE: HOPE AND CAUTION
STAGE IV, RECURRENCE, AND “THE PLAN”
THE SAFETY NET HOSPITAL: CULTURAL AND SOCIAL CHALLENGES
HOW WE TALK TO OURSELVES AND OUR COLLEAGUES
CONCLUSION
ACKNOWLEDGMENT
Specialized Care of the Terminally Ill
INTRODUCTION
EARLY SPECIALIST PALLIATIVE CARE
COMMUNICATION
SPECIFIC PROBLEMS IN THE SETTING OF ADVANCED CANCER
IMPENDING DEATH
CONCLUSION
PART IV Societal Issues
Cancer Survivorship
INTRODUCTION
DEFINITION OF SURVIVORSHIP AND SCOPE OF THE PROBLEM
GOALS OF SURVIVORSHIP HEALTH CARE
COMMUNICATION AND CARE COORDINATION
DELIVERY OF FOLLOW-UP CARE AND BEST PRACTICE MODELS
EDUCATIONAL CONSIDERATIONS
ENHANCING RESEARCH
FINANCIAL TOXICITY: EMPLOYMENT AND FINANCIAL HARDSHIP
CONCLUSION
Minority Health and Cancer Health Disparities
INTRODUCTION
MINORITY HEALTH RESEARCH
THE CAUSES OF CANCER
DISPARITIES IN SPECIFIC CANCERS
QUANTIFYING CANCER DISPARITIES IN THE UNITED STATES
Virtual Care and Telehealth in Oncology
INTRODUCTION
DEFINITIONS; TELEMEDICINE, TELEHEALTH, AND VIRTUAL CARE
TELEHEALTH METHODS
TYPES OF TELEHEALTH
CLINICAL IMPACT IN ONCOLOGY
FRAMEWORKS TO CONSIDER HOW TELEHEALTH FITS INTO CARE
TELEHEALTH BEST PRACTICES
REGULATORY COMPLIANCE, LEGAL AND BILLING
LICENSING, REIMBURSEMENT, AND LIABILITY
SUMMARY
Complementary, Alternative, and Integrative Therapies in Cancer Care
INTRODUCTION
LIFESTYLE MODIFICATIONS
MIND-BODY INTERVENTIONS
DIETARY SUPPLEMENTS AND NATURAL PRODUCTS
CONCLUSION
Index